Overview

Study of Roxadustat Conversion in Subjects Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Patients

Status:
Active, not recruiting

Trial end date:
2021-08-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and effectiveness of Roxadustat dosing regimens among hemodialysis subjects converted from ESA therapy or who are ESA-naïve.

Phase:

Phase 3

Details

Lead Sponsor:

FibroGen

Collaborator:

AstraZeneca